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ABSTRACT 
 
  APOBEC3G (Apo3G) is a host cell restriction factor of viruses that produce a single-
stranded (ss) DNA replication intermediate (Sheehy et al., 2002; Suspene et al., 2004). Apo3G is  
studied primarily for its ability to restrict propagation of the retrovirus, HIV.  In cell culture, 
Apo3G can only inhibit HIV if it lacks its virion infectivity factor (Vif).  The host-pathogen 
interface between Apo3G and HIV has become a new target of study for the development of 
novel HIV therapeutics (Prochnow et al., 2009; Sheehy et al., 2003). Apo3G induces 
mutagenesis of the HIV proviral DNA (Mangeat et al., 2003; Zhang et al., 2003). Apo3G has the 
ability to induce transition mutations, i.e. cytosine to thymine, through deamination of cytosine 
to form uracil. Deamination activity induces numerous mutations that causes gene inactivation of 
the HIV provirus thus restricting the HIV lifecycle.  Apo3G attenuates HIV virion infectivity in 
the absence of the virion infectivity factor (Vif) by inducing genome mutations through 
deamination of cytosine to uracil in HIV minus strand DNA.  Independent from deaminase 
activity, Apo3G may also interfere with HIV reverse transcription by preventing full length 
cDNA from forming (Iwatani et al., 2007), nucleocapsid (NC) mediated strand annealing (Guo et 
al., 2007; Guo et al., 2009; Li et al., 2007), and RNaseH activity of the reverse transcriptase (Li 
et al., 2007).  Whether Apo3G is able to restrict HIV by a deamination-independent mode 
remains controversial.  In particular, the existence of the deamination independent mode was 
challenged since the Apo3G deamination null mutant E259Q was shown to have limited or no 
ability to inhibit HIV-1 replication (Schumacher et al., 2008).  This research assesses the ability 
of Apo3G to inhibit reverse transcription of HIV genomic RNA.  It is hypothesised that based on 
the ability of Apo3G to bind and oligomerize on single stranded nucleic acids (Chelico et al., 2008), and 
its high affinity for RNA (Chelico et al., 2010), that Apo3G can inhibit RT mediated primer 
extension as well as nucleocapsid mediated strand annealing.  Additionally, it is hypothesized 
that Apo3G cannot inhibit RT RNAseH activity, as Apo3G has been shown to have a low 
affinity for  DNA/RNA hybrids (Iwatani et al., 2006).  We will test these hypotheses by using in 
vitro assays that mimic in vivo reverse transcription events.   
 Here we have shown that Apo3G is able to decrease the efficiency with which HIV-1 
reverse transcriptase synthesizes DNA from an RNA primer annealed to an RNA template. 
Apo3G had a minimal affect on primer initiation and primarily inhibits primer elongation. Using 
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the monomeric mutant, F126A/W127A, we show that the deamination independent mode of 
inhibiting reverse transcriptase is impaired without oligomerization on template RNA.  We also 
provide evidence that the Apo3G mutant E259Q should not be considered a deamination null 
proxy for native Apo3G since it exhibits decrease in RNA binding affinity compared to the 
native form.  We did not find that Apo3G inhibited HIV NC-mediated strand annealing activity 
or RNaseH activity of HIV-1 reverse transcriptase. The data suggest a two-tiered mechanism for 
inhibition of reverse transcriptase-mediated DNA synthesis that is dependent upon 1) the ability 
of Apo3G to oligomerize on RNA substrates and 2) bind RNA with high affinity.  Ascribing a 
mechanism to the deamination independent mode of HIV-1 restriction by Apo3G suggests that 
the enzyme may use this mechanism in vivo to delay completion of proviral DNA synthesis 
which, may negatively impact the HIV-1 lifecycle. 
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CHAPTER 1.0  
INTRODUCTION 
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1.1 General overview of APOBEC and the HIV-APOBEC3 host-pathogen interface 
 
 APOBEC3G is a member of a larger family of genes in the Apolipoprotein B editing enzyme, 
catalytic polypeptide (APOBEC or Apo) family that catalyze the deamination of cytosine to uracil in 
either DNA or RNA (Sawyer et al., 2004). The members of this family are Activation Induced 
Deaminase (AID), Apo1, Apo2, Apo3A-H and Apo4 (Chiu and Greene, 2008). Two notable members 
of this family, apart from Apo3G, are Apo1 and AID.  Apo1 edits the mRNA of apolipoprotein B 
which results is a truncated form of the apolipoprotein B lipid-transport protein, therefore modifying  
levels of low density lipoprotein production (Sawyer et al., 2004).  AID is an important player in 
antibody maturation in B-lymphocytes , and it is involved in generating antibody diversity and 
antibody class-switching (Sawyer et al., 2004). The original function of the Apo3 subfamily of 
enzymes is believed to be inhibition of endogenous retroelements, such as retrotransposons Alu, LINE-
1 or human endogenous retroelements (HERVs) (Chiu et al., 2006). Since retrotransposons are believed 
to be the origin of present day retroviruses and still display similar genetic replication features it is 
logical that Apo3 enzymes can act as potent inhibitors of both retrotransposons and retroviruses (Chiu 
et al., 2006).  That cytosine deaminases benefit humans, demonstrates that there is reward in their 
mutagenic functions, when tightly controlled, that outweighs the risk of possible aberrant mutagenesis 
in the cell. 
 Apo3G, the first Apo3 enzyme discovered, was shown to potently restrict the infectivity of HIV 
virions in the absence of the HIV virion infectivity factor (Vif)  (Sheehy et al., 2002).  Virions that do 
not contain Vif are rendered noninfectious in the presence of Apo3G.  Vif  blocks the antiviral activity 
of Apo3G by interfering with Apo3G mRNA translation (Stopak et al., 2003), blocking virion 
encapsidation of Apo3G (Kao et al., 2003), blocking deamination activity of Apo3G (Santa-Marta et 
al., 2005), and by increasing Apo3G protein degradation in conjunction with the 26S proteasome 
(Sheehy et al., 2002; Stopak et al., 2003), therefore depleting Apo3G levels and creating a permissive 
cell phenotype. Vif-mediated protein degradation of Apo3G is considered the most potent form 
inhibiting Apo3G antiviral activity. Vif mimics an E3 ubiquitin ligase protein resulting in 
ubiquitination and degradation of Apo3G-Vif-E3 complexes (Yu et al., 2003). Vif likely evolved in 
HIV as a means of host immune system evasion.  When Vif is absent, Apo3G renders HIV progeny 
virions noninfectious by deaminating cytosines to uracils in HIV cDNA or possibly by blocking 
synthesis of the proviral DNA. An overview of this host-pathogen interface is shown in Figure 1.1. 
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1.2 HIV Life-cycle/Replication 
  
 1.2.1 Viral Attachment and Entry 
  
 HIV utilizes host cellular receptors for attachment and entry.  The cellular receptors that are 
primarily used are CD4, and either CCR5 or CXCR4 (Friedrich et al., 2011).  CD4, a glycoprotein from 
the immunoglobulin superfamily, is expressed on helper and T regulatory cells, monocytes, 
macrophages, and dendritic cells and is a component of the T cell receptor (TCR) complex.  Normally, 
CD4 binds to Class II MHC molecules during antigen presentation to T cells and TCR activation 
(Friedrich et al., 2011).   The HIV surface glycoprotein, gp120, hijacks the CD4 molecule by binding to 
it upon attachment.  Once gp120 is bound to CD4, conformational changes allow a second surface 
protein, gp41, to insert its fusion peptide into the host cell membrane. This ultimately facilitates viral 
fusion and host cell entry (Gorry and Ancuta, 2011).    
  
 1.2.2 Proviral DNA synthesis  
 
Following viral attachment and entry, the positive (+) single stranded RNA genome of HIV 
must be converted into a double stranded DNA provirus before being integrated into the host genome.  
This occurs within the capsid.  The HIV enzymes required for reverse transcription of genomic RNA to 
dsDNA the provirus are nucleocapsid (NC) and reverse transcriptase (RT). RT, which functions as a 
heterodimer (66 and 51 kDa subunits), is a DNA polymerase that synthesizes the first (-) and second 
(+) DNA strands, and also has an RNAseH domain that degrades the RNA strand within DNA/RNA 
hybrids (Coffin, 1997). During synthesis of the second strand of DNA, degraded RNA either 
spontaneously dissociates from the nascent DNA or is easily displaced by RT. The NC protein has 
sequence-nonspecific nucleic acid destabilization and strand annealing activity, collectively called 
chaperone activity, (Bampi et al., 2004; Rein et al., 1998) that are essential for removing RNA 
secondary structure and chaperoning priming events that enable RT to complete its role (Figure 1.2). 
First, NC unfolds and anneals the host tRNALys,3 primer to the genomic RNA at a region near the 5'-end 
of the genomic RNA called the Primer Binding Site (PBS) to initiate synthesis of the minus strand 
DNA primer (strong stop DNA) (Figure 1.2 Step 1 and 2).  The host tRNALys,3 is specifically 
incorporated into the budding virion through an interaction with RT (Barat et al., 1989).  Later, NC 
transfers the DNA/ tRNALys,3 to 3'-end of the genomic RNA to prime (-)DNA synthesis (Bampi et al., 
4 
2004) (Figure 1.2 Step 3 and 4).  Second, NC transfers the (+) strand DNA, extended from the 
RNAseH-resistant polypurine tract (PPT) primers, to the 3'- end of the (-)DNA for second strand 
synthesis (Figure 1.2 Step 5and 6). NC also facilitates RT processivity (Grohmann et al., 2008).  
Following viral entry into the host cell, RT gains access to the host cell pool of deoxynucleotide 
triphosphates (dNTPs).  RT then recognizes the primer/template junction and begins incorporating 
dNTPs to synthesize (-) strand DNA (Coffin, 1997).  During first strand synthesis, after the RNA is 
degraded, Apo3G is able to deaminate cytosines to uracils on the minus strand DNA.  After completion 
of synthesis of the first DNA strand, the RT uses two RNAseH degradation resistant Polypurine Tracts 
(PPT) in the genomic RNA to prime second strand synthesis.  Synthesis of the second strand of DNA 
blocks any further Apo3G deaminations, but it also seals in the mutations induced by Apo3G. RT is 
highly error prone (Coffin, 1997), which is an advantage for HIV as the RT induced mutations help 
HIV to rapidly evolve and adapt. However, the mutations induced by Apo3G overcome the 
evolutionary flexibility in the HIV genome and cause gene inactivation (Pillai et al., 2008).   
 
 1.2.3 Integration, Assembly and Exit 
 
 Once reverse transcription is completed, the HIV proviral DNA is integrated into the host cell 
genomic DNA.  Recent models favor the uncoating of the viral capsid to allow nuclear entry (Arhel, 
2010).  HIV uses virus encoded integrase to insert proviral DNA into the host genome (Coffin, 1997).   
Once integrated, the provirus is transcribed using the host RNA polymerase.  Initial transcription events 
produce RNA that is translated into proteins. Late RNA synthesis produces nascent genomic RNA 
which is incorporated into assembling virions (Coffin, 1997).  To restrict HIV, Apo3G must be 
incorporated into assembling virus particles.  Incorporation involves the interaction of Apo3G with the 
NC region of the Gag polyprotein and/or RNA (Strebel and Khan, 2008).  It is thought that Apo3G can 
interact with either 7SL RNA or viral RNA in order to be incorporated into the nucleoprotein complex 
of the newly budding virions  (Strebel and Khan, 2008). Since Apo3G is compartmentalized in cellular 
RNA processing bodies (Gallois-Montbrun et al., 2006), it must bind to RNA that will be encapsidated 
into the virion in order to escape to another cellular localization (Soros et al., 2007). Only 7 ± 4 Apo3G 
molecules are encapsidated and are sufficient to hinder HIV replication upon a subsequent round of 
infection (Xu et al., 2007).   
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Figure 1.1 Inhibition of HIV by APOBEC3G that escapes Vif mediated degradation.  HIV Vif 
interacts with a cellular ubiquitin ligase complex to become the substrate recognition subunit of an E3 
ubiquitin ligase. The Vif-E3 complex recruits an E2 enzyme that transfers ubiquitin molecules to 
Apo3G, thereby signaling it for degradation through the proteasome pathway.  Apo3G that escapes 
degradation either fortuitously, or in the presence of a Vif-defective HIV strain, can enter an 
assembling virus particle through interactions with RNA (host 7SL RNA or HIV genomic RNA) and 
the NC portion of Gag.  Then, Apo3G travels with the HIV particle to the next target cell, akin to a 
‘Trojan Horse’, where it awaits for reverse transcription of the HIV genomic RNA to (-) DNA.  
Apo3G, a single-stranded DNA deaminase is able to deaminate cytosine (C) to uracil (U) in (-) DNA, 
and causes the RT to introduce guanine (G) to adenine (A) mutations upon using uracil-containing (-) 
DNA as a template to synthesize (+) DNA. This creates a hypermutated and likely inactivated virus. 
Apo3G may also physically inhibit the accumulation of reverse transcripts in a manner that is 
deamination independent. 
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Proteasome
Virion 
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Producer Cell
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C/GT/A 
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Integration
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U
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Figure 1.2 Schematic of reverse transcription and replication of the HIV RNA genome into the 
proviral DNA.  The genomic RNA (black line) is primed for replication using a host tRNALys,3 primer 
(Step 1). The NC protein facilitates the transfer of primers to initiate first strand ((-)DNA) and second 
strand ((+)DNA) synthesis (Steps 2 and 5).  The RT synthesizes the DNA (bold line) and degrades the 
RNA (hatched line) with its RNAseH domain (Steps 4 and 6).  In the time between (-)DNA synthesis 
and (+)DNA synthesis, single-stranded regions of the (-)DNA become substrates for Apo3G-catalyzed 
deaminations.  Abbreviations are: R, repeated sequence; U5, unique 5'-region; PBS, primer binding 
site; PPT, polypurine tract; U3, unique 3'-region. 
 
1.3 Biochemistry of APOBEC3G 
 
 1.3.1 APOBEC3G Deamination activity in vitro 
 
Apo3G has two cytosine deaminase domains (CD) in contrast to APOBEC1 and AID which 
have only one domain (Chiu and Greene, 2008).  The domains are known as CD1 and CD2 and are 
located in the N- and C- termini of the enzyme, respectively.  However, in Apo3G, only the CD2 is 
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catalytically active.  The CD1 is able to bind nucleic acids and is necessary for incorporation of Apo3G 
into HIV virions (Navarro et al 2005).  The CDs of all APOBEC family members can be characterized 
as having a consensus zinc-binding deaminase motif His-X-Glu-X23-28-Pro-Cys-X2-4-Cys, where X 
symbolizes any amino acid (Harris and Liddament, 2004).  The cytosine deaminases harbor similar 
core structural features, including a typical core β-sheet consisting of five β-strands and an active site 
containing a zinc atom coordinated by three residues (two Cys and a His/Cys) from the second and 
third helices (Bransteitter et al., 2009).  This is a canonical type of zinc coordination with a centrally 
located Zn atom that can interact with a water molecule and become activated.  The water molecule 
serves as a hydrogen donor during the deamination process.  The conserved glutamate residue, E259 in 
Apo3G, facilitates catalysis by it functioning as a proton shuffler for the hydrolytic reaction 
(Bransteitter et al., 2009). The glutamate residue is likely responsible for the amine group removal from 
cytosine, which forms uracil (Harris and Liddament, 2004), as shown in Figure 1.3A.  The deamination 
reaction of Apo3G shows marked specificity for 5'CCC repeats (Chelico et al., 2006).  Apo3G 
deaminates cytosine processively, meaning that it has the ability to deaminate multiple cytosine 
residues  on a single DNA target before dissociation (Chelico et al., 2006).   
 
1.3.2 APOBEC3G oligomerization  
 
Apo3G has been shown to form oligomers and exists as monomers, dimers, tetramers and even 
higher order structures (Chelico et al., 2010; Chelico et al., 2008).  In solution, Apo3G is a monomer or 
dimer. Upon binding ssDNA or RNA, Apo3G oligomerizes into dimers, tetramers and higher order 
structures (Chelico et al., 2010; Chelico et al., 2008).  The F126A/W127A (F/W) mutant, which has 
been shown to exist as a monomer in solution and when bound to DNA or RNA, demonstrates that 
Apo3G dimerization is specific to a region in the N-terminus and tetramer formation through the C-
terminus is hierarchically dependent on dimerization (Chelico et al., 2010; Huthoff et al., 2009).   
 
1.4 Clinical studies of APOBEC3G inhibition of HIV 
 
 Apo3G is the model deaminase from the Apo3 family and appears to be the most effective 
restrictor of HIV replication as measured by cell-based assays (Bishop et al., 2004; Han et al., 2004; 
Zennou and Bieniasz, 2006) and suggested by mRNA expression (Koning et al., 2009; Refsland et al., 
2010) and clinical studies (Biasin et al., 2007; Knopp et al., 2003; Patel et al., 2002; Ulenga et al., 
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2008; Vazquez-Perez et al., 2009; Xu et al., 2003). Clinical subjects found to have an inherent ability to 
express a high level of Apo3G are less likely to become infected with HIV or progress from HIV to 
AIDS (Biasin et al., 2007; Knopp et al., 2003; Koning et al., 2009; Patel et al., 2002; Refsland et al., 
2010; Ulenga et al., 2008; Vazquez-Perez et al., 2009; Xu et al., 2003). Evidence of deaminations in 
HIV genomes recovered from patients carry C/G→T/A mutations in a sequence context that indicates 
deaminations by Apo3G occur most frequently (Knopp et al., 2003; Patel et al., 2002; Vazquez-Perez 
et al., 2009).   
 Further evidence of the clinical relevance of Apo3G is from the clinical Apo3G mutant, H186R. 
Accelerated AIDS progression is associated with the clinical Apo3G mutant H186R.  This single 
nucleotide polymorphic variant has been shown to be prevalent among African Americans and rare in 
European Americans or Europeans (An et al., 2004).  When present in HIV positive African 
Americans, the H186R mutation is associated with accelerated AIDS progression.   The H186R mutant 
has been found to have an altered processive mechanism compared to native Apo3G that leads to fewer 
deamination-induced mutations in a reconstituted HIV replication system (Feng and Chelico 2011). 
The biochemical difference may contribute to the decreased effectiveness seen in clinical studies. 
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Figure 1.3 Deamination of cytosine to uracil in DNA is mutagenic. (A) Apo3G catalyzes the 
deamination of cytosine (position 4), to form uracil. Uracil is mutagenic in DNA because when 
polymerases encounter uracil in the template during DNA synthesis, the original C/G basepair is 
converted to a T/A basepair. (B)  Illustration of how cytosine deamination can lead to a mutation. 
Apo3G can deaminate cytosines on the first strand of DNA synthesized ((-)DNA) from the RNA 
genome of HIV. Apo3G prefers to deaminate the third C in the motif, 5'CCC. Upon synthesis of the 
second strand of DNA ((+) DNA), the reverse transcriptase of HIV will “read” the uracil as a thymine 
and insert an adenine while the original genome sequence had a guanine at this position. Apo3G 
catalyzes deaminations at numerous positions on the HIV (-) DNA. Multiple A/T base pair 
substitutions result in production of defective viral proteins and loss of infectivity. 
 
1.5 Modes of HIV restriction by APOBEC3G 
  
There are two possible modes by which Apo3G functions to thwart HIV, one mode being 
deamination dependent and the other mode being deamination independent.  Deamination and its 
effects on HIV have been unequivocally demonstrated (Mangeat et al., 2003; Zhang et al., 2003). 
However, whether a deamination independent mode exists remains controversial. Since the 
deamination independent mode would occur first, to inhibit minus strand synthesis, then the 
deamination based mode could be considered only a back-up mechanism for Apo3G. This hypothesis 
has merit since the original function of inhibiting retrotransposons by Apo3G occurred solely by 
binding transposon RNA and shuttling it to RNA degradation bodies, a deamination independent 
A B CCC5' cDNA/(-)DNA
Apo3G
CCU5' (-)DNA
CCU5' (-)DNA
GGA3' (+)DNA
CCT5'
GGA3'
provirus
DNA repair
Second strand synthesis
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mechanism (Chiu et al., 2006). 
  
 1.5.1 Deamination dependent mode of APOBEC3G inhibition of HIV 
 
The result of the deamination dependent mode is the deamination of cytosine to uracil in the 
first strand of DNA synthesized from the HIV RNA genome. Since Apo3G is a single-stranded DNA 
deaminase, the deamination activity is limited to the first strand of DNA only (Figure 1.2). The minus 
strand then serves as a template for plus strand synthesis and the dU residues are templates for the 
incorporation of dA (Figure 1.3B).  The result is a dG-to-dA hypermutated virus with an altered viral 
open-reading frame having nonsense and missense mutations (Chiu and Greene, 2009).  In addition to 
this, accumulating dUs in the minus strand DNA may lead to a decrease in plus strand synthesis due to 
aberrant initiation (Chiu and Greene, 2009).   
 
 1.5.2 Deamination independent mode of APOBEC3G inhibition of HIV 
 
 The literature concerning the deamination independent mode of Apo3G is filled with 
controversial reports. The deamination independent mode has been shown to decrease the accumulation 
of early and late reverse transcripts by up to 50-90% (Bishop et al., 2006; Guo et al., 2006; Iwatani et 
al., 2007; Li et al., 2007; Mangeat et al., 2003; Newman et al., 2005). However, others have reported 
that Apo3G does not have a deamination independent mode and claim that deamination is the only 
mode that Apo3G utilizes to restrict HIV (Mbisa et al., 2007; Miyagi et al., 2007; Schumacher et al., 
2008).   
In this M.Sc. research project we used a new research approach, a series of stepwise focused 
biochemical experiments, to reconcile the literature in the field. For those who do subscribe to a 
deamination independent mode there are two competing theories that are the most prevalent;  that 
Apo3G inhibits RT polymerization and possibly RNAseH activity (Iwatani et al., 2007; Li et al., 2007) 
or that Apo3G inhibits NC mediated RNA annealing (Guo et al., 2006).  
Apo3G inhibition of RT polymerization was concluded to be evident since it reduces the 
accumulation of reverse transcripts in vivo (Mangeat et al., 2003).  One theory is that the ability of 
Apo3G to bind nucleic acids is central to its deamination independent mechanism.  It has been 
hypothesized that the N-terminal domain (CD1) binds to viral RNA/DNA and decreases the 
polymerization efficiency of RT (Iwatani et al., 2007).   The steady state dissociation constant (Kd) of 
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Apo3G for bacteriophage lambda DNA is 8- fold less than that of RT so Iwatani et al concluded that 
Apo3G could successfully out compete RT for DNA/RNA substrates (Iwatani et al., 2007).  This 
characteristic is likely due to the ability of Apo3G to oligomerize on nucleic acids into dimers, 
tetramers, and other higher order forms (Chelico et al., 2008). It is also hypothesized that Apo3G can 
interact directly with RT (Douaisi et al., 2004).  Although one study found that there was no direct 
interaction between Apo3G and RT (Iwatani et al., 2007), another study, based on qualitative data from 
immunoprecipitation assays, found that that Apo3G and RT likely interact (Douaisi et al., 2004). The 
hypothesis of Douaisi et al. is that Apo3G may act by binding to RT and reducing its activity.   
The doubts in the existence of a deamination independent mode came from two lines of 
evidence. First, some research groups found that the decrease in the accumulation of HIV reverse 
transcripts only occurred at a high transfection level of exogenous Apo3G into 293T cells (Miyagi et 
al., 2007; Schumacher et al., 2008).  When transfection levels were decreased to mimic cellular levels 
of Apo3G the deamination independent mode of inhibition was not detected.  Second, the catalytically 
inactive mutant of Apo3G, E259Q, has been used to test the deamination independent mode of 
inhibition as groups have seen a 40-100% decline in the inhibition of reverse transcripts, suggesting 
that deamination is necessary (Bishop et al., 2008; Mbisa et al., 2007; Miyagi et al., 2007; Schumacher 
et al., 2008).  However in research that has used the E259Q mutant as a “control” for a deamination 
null form of Apo3G, it has never been established that despite lacking deamination activity, this mutant 
is a biochemically equivalent version of Apo3G. Mutating regions of an enzyme near the Zn 
coordination residues can cause structural changes since the Zn molecule is an important part of the 
internal scaffold of enzyme structure. 
 
1.6 Hypothesis and Objectives 
 
 This research project will assess the ability of Apo3G to inhibit events necessary for reverse 
transcription of HIV genomic RNA.  It is hypothesized that Apo3G can inhibit RT mediated primer 
extension and nucleocapsid (NC) strand annealing though the ability of Apo3G to bind and oligomerize 
on single stranded nucleic acids (Chelico et al., 2008).  Unless we find that there is a strong protein-
protein interaction between RT and Apo3G, it is hypothesized that Apo3G cannot inhibit RNAseH 
activity of RT because of a low affinity for binding DNA/RNA hybrids (Iwatani et al., 2006).  
 We are mindful that the research is in vitro and will be using levels of enzymes that mimic the 
concentrations encountered in a virion in vivo (Table 1.1).  The concentrations of enzymes and RNA 
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were added at ratios that mimic the predicted concentration in a ΔVif HIV virion with a 60 nm radius 
(Briggs et al., 2004; Coffin, 1997; Xu et al., 2007; Zhu et al., 2003a).  
 This aim of this project is to assess the deamination independent mode that Apo3G potentially 
utilizes to restrict HIV through the following approaches: 
 
(1) Testing to see if Apo3G can inhibit polymerization of a primer/template by RT or degradation of 
the genomic RNA by the RNAseH domain of RT after cDNA synthesis. 
 - Here we have used in vitro assays using radionucleotide labeled substrates to detect either 
polymerization efficiency or RNAseH degradation efficiency. 
 
(2) Testing to see if Apo3G can interfere with the first strand primer (tRNALys,3) annealing in the PBS 
of the HIV genome. This step is critical for minus strand DNA synthesis and is mediated by NC. 
 - Here we have used an established strand annealing assay used to study NC strand annealing 
activity. 
 
(3) Establishing the mechanism of inhibition using experiments that will be designed based on results 
of objectives (1) and (2).  
 - Here we have used the technique of rotational anisotropy (fluorescence depolarization) to 
quantify protein-protein or protein-nucleic acid interactions.  
 
Table 1.1 Estimated concentration of reverse transcription components in an HIV-1 virion. 
 
 Number molecules 
per virion 
Concentration 
(60 nm virion 
radius) 
Molar ratio 
to genome 
Reference 
genomic RNA 2 3.7 µM -- (Coffin, 
1997) 
nucleocapsid 1400-5000 6  3 mM 1621  (Briggs et 
al., 2004; 
Zhu et al., 
2003b) 
reverse transcriptase 100 180 µM 48  (Coffin, 
1997) 
Vif 7-20 25  12 µM 7  (Camaur 
and Trono, 
1996) 
Apo3G (Δvif HIV-1) 3-11 13  8 µM 4  (Xu et al., 
2007) 
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2.1 Site-directed mutagenesis and cloning 
 
 Primers are listed in Table 2.1 and were purchased from Integrated DNA Technologies.  Site-
directed mutagenesis to construct the Apo3G E259Q clone was conducted previously in our lab 
(unpublished data) using the QuikChange site-directed mutagenesis protocol with the pAcG2T-Apo3G 
vector as the template (Chelico et al., 2006). Construction of native Apo3G, Apo3G F126A/W127A 
(F/W mutant), and NC have been described previously (Chelico et al., 2010; Feng and Chelico, 2011).  
 For the RNA template,  a 104-nucleotide (nt) segment near the 5'-end of the HIV-1 genome (nt 
571-674, Table 2.1) from the HIV-1 clone 93th253.3 (GenBank accession number U51189) 
encompassing the PBS and upstream region was PCR amplified and cloned into the BamHI and EcoRI 
sites of the pSP72 vector (Promega). The HIV-1 clone was obtained through the AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, National Institutes of Health; p93TH253.3 was 
from Dr. Feng Gao and Dr. Beatrice Hahn (Gao et al., 1996).   
 
2.2 Protein expression and purification 
 
 Recombinant baculoviruses expressing GST-NC and GST-Apo3G proteins (native and mutant) 
was constructed as described previously (Chelico et al., 2006; Feng and Chelico, 2011). Sf9 cells were 
infected with recombinant NC or Apo3G virus at a multiplicity of infection of 1 and harvested after 72 
h. Cells were lysed and proteins purified, as described previously, to obtain NC or Apo3G protein 
cleaved from the GST tag (Chelico et al., 2010; Feng and Chelico, 2011). Cleaved protein fractions 
were stored at −70 °C. The NC and Apo3G forms are >95% pure. Proteins were previously purified in 
the lab except E259Q which was purified for this study. Purified HIV-1 RT p66/p51 (Le Grice and 
GrÜNinger-Leitch, 1990) was generously provided by Dr. Stuart F. J. Le Grice (NCI, National 
Institutes of Health).  
 
2.2.1 Protein Purity 
 
 Two micrograms of purified native, F/W, E259Q and H186R Apo3G were resolved by 12% 
SDS-Polyacrylamide Gel Electrophoresis (PAGE).  Before loading, the proteins were denatured by 
addition to 1x SDS sample buffer (50 mM Tris pH 6.8, 2% SDS, 10% glycerol, 1% β-mercaptoethanol, 
12.5 mM EDTA, 0.02% bromophenol blue) and heating at 65ºC for one minute.  The SDS-PAGE gel 
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was resolved at 150 Volts until the bromophenol blue reached the bottom of the gel.  The gel was then 
stained with coommassie (0.1% coommassie blue R-250, 45% methanol, and 10% glacial acetic acid).  
The gel was then destained in 10% glacial acetic acid and 10% Methanol and visualized with a Bio-
Rad Chemidoc (Figure 2.1). 
 
Figure 2.1 Protein purity verification Native, E259Q, F/W and H186R Apo3G were resolved on a 12 
% SDS-PAGE gel and stained with coommassie.  Native and mutant Apo3G (46.4 kDa) resolve as a ~ 
40 kDa protein.  This gel verifies the enzymes are >95% pure.  
 
2.3 In vitro RNA production 
 
 The pSP72-RNA template vector described in Section 2.1 was purified from DH5α Escherichia 
coli and linearized with EcoRI to be used as a substrate for T7 RNA polymerase-mediated 
transcription, as per manufacturer’s instructions for RNA (Promega) or fluorescein (F) labeled (F-UTP) 
RNA (Roche). 
 
2.4 Radiolabeling of oligonucleotides  
   
2.4.1 5'-end labeling of synthetic RNA 
 
 One micromolar of the RNA Primer (Table 2.1) was labeled in a 10 µL reaction consisting of  1 
unit of  Polynucleotide Kinase (PNK) (New England Biolabs), 1X PNK buffer, 700 nM of  γ-32P ATP 
(6000 Ci/mmol, Perkin –Elmer), and 4.75 µL of ddH2O. The reaction was heated at 37 ºC for 45 min 
and then the PNK was inactivated by heating at 95 ºC for 10 min.  
MW
kD
250
150
100
75
50
37
25
20
15
16 
2.4.2 5'-end labeling of in vitro transcribed RNA 
 
 The template RNA was produced by in vitro T7 polymerase mediated transcription, as 
described in Section 2.3. Radiolabeling was accomplished by first dephosphorylating the template 
RNA with 2 units of Antarctic Phosphatase (New England Biolabs) according to the manufacturer’s 
instructions with provided buffer in a 10 µL reaction, which was scaled up accordingly, at 37 oC for 60 
min with subsequent heat inactivation at 65 oC for 5 min.  The 5'-end dephosphorylated RNA was then 
5'-end labeled using γ-32P-ATP using a 70 % labeling efficiency (6000 Ci/mmol, Perkin –Elmer) with 2 
units of Polynucleotide Kinase (New England Biolabs) in a 10 µL reaction, which was scaled up 
accordingly, at 37 oC for 45 min with subsequent heat inactivation at 95 oC for 10 min.   
 
2.4.3 Internal labeling of in vitro transcribed RNA 
 
Internally α-32P CTP labeled RNA template was synthesized using a Riboprobe® in vitro Transcription 
kit (Promega).  The 20 µL labeling reaction  consisted of 4µL of Transcription Buffer (Promega), 2µL 
of 100 nM DTT, 20u of Recombinant RNasin® Ribonuclease Inhibitor (New England Biolabs), 4µL of 
a solution containing 2.5 mM rATP, rGTP, and rUTP, 2.4 µL of 100 µM rCTP, 1 µL of 1.0 mg/ml 
linearized template DNA, 50 µCi α-32P CTP in 5 µL and 1µL of T7 RNA Polymerase. The reaction 
was incubated for 1 hr at 37ºC.  Following this, 1uL of DNAseI was added to the reaction and was 
incubated for 15 minutes at 37ºC.  The internally labeled template RNA was then purified by extraction 
with low pH Phenol:Chloroform (Ambion). The recovered aqueous phase was passed through a P-6 
Biospin column (Bio-Rad) to remove unincorporated nucleotides. 
  
2.5 Nucleocapsid-mediated strand annealing assay 
 
 The annealing assay reactions contained 5' end labeled template RNA (Section 2.4.2, 20 nM), 
Human tRNALys,3 (40 nM, BioS&T Montreal, Quebec), annealing assay buffer (20 mM Tris pH 7.5, 30 
mM NaCl, 0.1 mM MgCl2, 10 µM ZnCl2 and 5 mM DTT), Recombinant  RNasin® Ribonuclease 
Inhibitor (1unit, New England Biolabs), and NC (50-1700 nM).   Native, E259Q, F/W mutant and 
H186R Apo3G were added at either 80 nM or 640 nM concentrations.  Samples of 2.5 µL were taken 
at 5, 10 and 30 min and stopped by adding the sample to a solution which contained 0.5 mg/ml 
Proteinase K (New England Biolabs) in annealing assay buffer and incubated at 20oC for 20 min. 
17 
Afterwards, loading dye was added to a concentration of 1x (50 mM Tris, pH 7.5, 4% glycerol, 0.01% 
w/v xylene cyanol, and 0.01% w/v bromophenol blue). Two and a half microlitres of sample were 
resolved on an 8% non-denaturing polyacrylamide gel. The gels were then dried for 2 hours and the 
bands were visualized by phosphorimaging with a Typhoon phosphorimager (GE Healthcare). 
 
2.6 Primer extension assay 
 
 Primer extension assays were employed to measure RT elongation activity with and without 
Native Apo3G and mutant enzymes.  The template RNA was heat annealed to a 5'-32P-labelled 
synthetic RNA primer (Section 2.4.1, Table 2.1). The primer/template (20 nM) was then used in 
reactions containing RT buffer (50mM Tris, pH 7.5, 40 mM KCl, 10 mM MgCl2, 1 mM DTT), 500 µM 
dNTPs, 960 nM RT with or without 350 nM NC, and Apo3G (native, F/W mutant,  E259Q, or H186R) 
at either 80 or 640 nM.  Reactions were preincubated at 37 °C for 1 min before the addition of dNTPs 
which were used to start the RT elongation reaction. The enzymes were added at specific ratios to the 
primer/template to mimic the predicted concentrations in an HIV virion with a 60 nm radius (Briggs et 
al., 2004; Coffin, 1997; Xu et al., 2007; Zhu et al., 2003a), excluding the reaction with 640 nM of 
Apo3G. Reactions were stopped by adding a 4-fold excess of 20 mM EDTA and 95% formamide.  
Primer extension was visualized by resolving samples on a 16% denaturing urea-polyacrylamide gel.  
Gel band intensities were measured by phosphorimaging with a Bio-Rad FX scanner or Typhoon 
imager (GE Healthcare) and analyzed with ImageQuant software (GE Healthcare).  
 
2.7 Rotational anisotropy  
 
2.7.1 Protein-RNA steady state rotational anisotropy assays 
Rotational anisotropy was measured with a QuantaMaster QM-4 fluorometer (Photon 
Technology International).  Fluorescein labeled samples were excited with vertically polarized light at 
494 nm, and both vertical and horizontal emissions were monitored at 520 nm (3.5-nm band pass). 
 
2.7.1.1 Reverse transcriptase and APOBEC3G with RNA 
 
 To measure the affinity of RT and Apo3G (Native and mutant enzymes) for the primer/template 
RNA, Protein-RNA steady state rotational anisotropy assays were utilized.  A 5'-end fluorescein 
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labeled RNA primer (Integrated DNA Technologies) (Table 2.1) was heat annealed to the template 
RNA to form the primer/template binding substrate at a ratio of 1:1.5.  The reactions (80 µL) were 
incubated at 37 °C and contained RT buffer and primer/template (30 nM).  Increasing concentrations 
(0-2100 nM) of either RT, native Apo3G, F/W mutant or E259Q were then added to the 
primer/template containing RT buffer. 
 
2.7.1.2 Nucleocapsid and APOBEC3G with RNA 
 
 To measure NC and Apo3G binding, a fluorescein labeled template RNA (Section 2.3) was 
used as the binding substrate for experiments involving Apo3G and NC.  The reactions (80 µL) were 
incubated at 37 °C and contained RT buffer, fluorescein labeled template RNA (50nM), and either 
increasing concentrations of Apo3G (0-2100 nM) with or without 500 nM or 850 nM NC prebound to 
the fluorescein labeled template RNA or increasing concentrations of NC (0-2100 nM) with or without 
500 nM or 850 nM Apo3G prebound to the fluorescein labeled template RNA. 
Rotational anisotropy was measured with a QuantaMaster QM-4 fluorometer (Photon 
Technology International).  Samples were excited with vertically polarized light at 494 nm, and both 
vertical and horizontal emissions were monitored at 520 nm (3.5-nm band pass). 
 
2.7.2 Protein-Protein steady state rotational anisotropy assays 
 
To measure how Apo3G interacted with RT and the F/W mutant, Protein-Protein steady state 
rotational anisotropy assays were employed.  Native Apo3G was labeled with flourescein (F) using the 
Fluorescein-EX Protein Labeling Kit (Molecular Probes). Fifty nanomolar of F-Apo3G was used in a 
reaction mixture (80 μL) containing RT buffer and a titration of RT, native Apo3G or F/W mutant (0-
11 μM). Reactions were monitored at 37 °C.  Rotational anisotropy was measured using a 
QuantaMaster QM-4 fluorometer (Photon Technology International) with a single emission channel. 
Samples were excited with vertically polarized light at 494 nm, and both vertical and horizontal 
emission were monitored at 520 nm (5 nm band pass). 
 
2.8 Electrophoretic mobility shift assay 
 
 To assess the ability of Apo3G and mutant enzymes to compete with RT for binding the primer 
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template (Table 2.1), electrophoretic mobility shift assays were utilized.  A 5'-end fluorescein labeled 
RNA primer (Integrated DNA Technologies) (Table 2.1) was heat annealed to the template RNA 
(Table 2.1) at a ratio of 1:1.5 to form a primer/template binding substrate. The reactions (10 µL) were 
incubated for 5 minutes at 25 °C and contained RT buffer, primer template (50 nM), and 4% glycerol, 
with or without prebound native Apo3G (480 nM). Increasing concentrations of RT (0-2480 nM) were 
added to the reaction.  Band shifting, indicating RNA binding, was visualized by resolving samples on 
an 8% non-denaturing polyacrylamide gel.  Gel bands were visualized by scanning with a Typhoon 
imager (GE Healthcare).  
 
2.9 Pyrrolo-C fluorescence based assay 
 
 The detection of protein induced conformational changes in primer/template RNA that may be 
caused by Native Apo3G and the F/W and E259Q mutants was assessed by using Pyrrolo-C 
florescence assays.  Pyrollo-dC is a fluorescent nucleotide analogue that can be used to monitor 
changes in the local structure of the ssDNA (Chelico et al., 2008).  A 60 nt pyrrolo-C labeled RNA 
(100nM) (Table 2.1), purchased from Tri-Link Biotechnologies, was added to a reaction mixture (80 
μL) containing 50 mM Tris, pH 7.5, 2.5 mM MgCl2 and 1.2 μM of either native Apo3G, E259Q or 
F/W mutant.  Reactions were incubated at 25 °C.  Samples were excited at 345 nM (10 nm band pass) 
and the emissions were scanned (1 nm/second) with a range from 410-510 nM.  The 450 nm emissions 
peak was used to calculate the relative fluorescence emissions of each enzyme with the RNA compared 
to RNA alone. 
 
2.10 RNAseH assay 
 
 To determine the ability of Apo3G and mutant enzymes to inhibit RT mediated RNAse H 
activity, RNAseH assays were used.  Internally α-32P CTP radiolabelled RNA (20 nM, Section 2.4.2) 
was either annealed to a full length complementary DNA or an RNA primer (Table 2.1).  The relevant 
substrate was then used in reactions containing RT buffer, 500 µM dNTPs, 960 nM RT, 350 nM NC, in 
the absence or presence of Apo3G (native, F/W mutant,  E259Q, or H186R) at either 80 or 640 nM.   
The enzymes were added at specific ratios to the primer/template to mimic the predicted 
concentrations in an HIV virion with a 60 nm radius (Briggs et al., 2004; Coffin, 1997; Xu et al., 2007; 
Zhu et al., 2003a), excluding the reaction with 640 nM of Apo3G. Reactions were stopped by adding a 
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4-fold excess of 20 mM EDTA and 95% formamide.  RNA degradation was visualized by resolving 
samples on a 16% denaturing urea-polyacrylamide gel.  Gel band intensities were measured by 
phosphorimaging with Typhoon imager (GE Healthcare) and analysis with ImageQuant software (GE 
Healthcare). 
 
Table 2.1 Primers and substrates. 
 
Name Sequence 
E259Q SDM Forward CCT TGA AGG CCG CCA TGC ACA GCT GTG CTT CCT GGA CGT 
GAT TC 
E259Q SDM Reverse GAA TCA CGT CCA GGA AGC ACA GCT GTG CAT GGC GGC CTT 
CAA GG 
Template RNA cloning 
primer (Forward) 
GAA TTC CCC TAT TAA CTT TCG CTT TCA AG 
 
Template RNA cloning 
primer (Reverse) 
AGA TCT TGT TAG GAC TCT GGT AAC TAG AG 
Template RNA  UGU UAG GAC UCU GGU AAC UAG AGA UCC CUC AGA UCA CUC 
UAG ACU GAG UAA AAA UCU CUA GCA GUG GCG CCC GAA CAG 
GGA CUU GAA AGC GAA AGU UAA UAG GG 
Full Complement DNA CCC TAT TAA CTT TCG CTT TCA AGT CCC TGT TCG GGC GCC 
ACT GCT AGA GAT TTT TAC TCA GTC TAG AGT GAT CTG AGG 
GAT CTC TAG TTA CCA GAG TCC TAA CA 
RNA Primer GUC CCU GUU CGG GCG CCA CUG CUA 
Fluorescein labeled 
RNA primer 
(FAM)GU CCU GUU CGG GCG CCA CUG CUA 
Pyrrolo-C RNA AUU AUU AUU AUU AUU AUU AUU CCC CC(P-C) AUU UAU UUA 
UUU A CCC CCC AUU UAU AUU AUU AU 
Abbreviations: FAM is fluorescein, P-C is pyrrolo-C. 
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3.1 The influence of APOBEC3G on Nucleocapsid-mediated tRNALys,3 annealing  
 
3.1.1 The effect of APOBEC3G on Nucleocapsid-mediated annealing of tRNALys,3 to the primer 
binding site of HIV RNA 
 
We hypothesized that since Apo3G can bind to RNA that it might inhibit the ability of NC to 
facilitate the annealing of tRNALys,3 to the RNA.  This assay was chosen as it models the initial step of 
HIV replication, the annealing of the host tRNALys,3 to the HIV genomic PBS. The 32P-labelled 104 nt 
single stranded template RNA containing the PBS region is incubated with a folded tRNALys,3 and NC 
in the absence or presence of Apo3G. Annealing of the tRNALys,3  to the template RNA is monitored by 
the formation of a higher molecular weight product on the gel. By itself the 32P-labelled template RNA 
appears as a single band (Figure 3.1, lane 1).  When tRNALys,3 is heat annealed to the RNA the band 
shifts upwards due to an increase in mass (Figure 3.1, lane 3).  When tRNALys,3 is added without heat 
annealing to the RNA, no discernible band shifts are detected because the tRNALys,3 requires unfolding 
by NC.  When NC and the tRNALys,3 are present with the template RNA, band shifts are detected as 
early as 5 min and increase in population after 10 and 30 minutes (Figure 3.1, lanes 4,5 and 6, 
respectively).  This demonstrates that the in vitro assay can model NC-mediated strand annealing of 
tRNALys,3 to the HIV PBS embedded within the RNA.  
However, when Apo3G is added to the reaction at a ratio of 4 Apo3G: 1 template RNA, the 
ratio estimated to be present in virions (see Table 2.1) it appears not to be able to inhibit strand 
annealing (Figure 3.1, lanes 7, 8 and 9) as no discernible difference between the shifting of these lanes 
and those with NC only (Figure 3.1, lanes 4, 5 and 6) are detected.  Increasing the concentration of 
Apo3G to 32-fold more than the template RNA does not appear to overcome this (Figure 3.1, lanes 10, 
11 and 12).  The Apo3G monomeric F/W mutant and the Apo3G catalytic mutant, E259Q, also appear 
to have no effect on NC-mediated tRNALys,3 strand annealing (data not shown). 
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Figure 3.1 Apo3G does not inhibit Nucleocapsid mediated strand annealing.  Template RNA (104 
nt) 32P labeled at the 5'-end was added to reactions at a concentration of 20 nM.   NC was added at a 
concentration to saturate the RNA (85:1, 1700 nM) as it binds 1 NC per 7 nt (Rein et al., 1998).  The 
4:1 ratio of Apo3G to template RNA (80 nM Apo3G) represents the concentration of Apo3G estimated 
to be found in a ΔVif HIV virion (see Table 2.1).  NC alone (lanes 4-6) or in the presence of either a 4:1 
Apo3G (lanes 7-9) or 32:1 ratio of Apo3G to the template RNA (lanes10-12) was tested. Samples were 
taken at 5, 10 and 30 min. Groups of timed assays are denoted with a triangle.  Template RNA by itself 
(lane 1) and template RNA with tRNALys,3, but in the absence of NC (lane 2) are negative controls. 
Lane 3 is with the tRNALys,3 heat annealed to the template RNA  which serves as a positive control. 
 
3.1.2 Determining the minimal concentration of nucleocapsid that can promote annealing of 
tRNALys,3 to the primer binding site of HIV RNA 
 
 When NC was present at an 85-fold excess to the template RNA, Apo3G at both the 4:1 and 
32:1 ratios over the template RNA were both shown to not interfere with NC mediated tRNALys,3 to the 
PBS region of the template RNA (Figure 3.1).  We hypothesized that lowering the concentration of NC 
may allow Apo3G to compete better with NC for RNA, therefore allowing Apo3G to prevent NC from 
facilitating tRNALys,3 annealing.  Titrating the concentration of NC (Figure 3.2) reveals that an NC ratio 
to the template RNA as low as 21:1 (425 nM) still allows NC to facilitate tRNALys,3 annealing (Figure 
3.2 lanes 8, 9 and 10).   
Annealed
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Figure 3.2 Titration of nucleocapsid concentration. Template RNA (104 nt) 32P-labeled at the 5'-end 
was added to reactions at a concentration of 20 nM.   NC was added to the reactions at ratios to the 
template RNA of 85:1 (lanes 2-4), 43:1 (lanes 5-7), 21:1 (lanes 8-10), 11:1 (lanes 12-14), 5:1 (lanes 
15-17) and 2.5:1 (lanes 18-20).  Template RNA by itself (Lane 1 and 11) serves as a negative control. 
Samples were taken at 5, 10 and 30 min. Groups of timed assays are denoted with a triangle.  
 
3.1.3 Nucleocapsid-mediated annealing of tRNALys,3 to the primer binding site of HIV RNA in the 
presence of native and mutant APOBEC3G  
 
 Using the ratio of 21:1 NC to template RNA determined from Figure 3.2 to be the lowest 
concentration of NC that could facilitate tRNALys,3 annealing,  a 4:1 ratio of Apo3G (native and 
mutants) to template RNA were added to the annealing assay reactions (Figure 3.3).  This method was 
chosen to assess whether or not having protein concentrations in favor of Apo3G inhibition (higher 
Apo3G and lower NC concentrations) would better enable Apo3G to inhibit NC mediated tRNALys,3 
annealing to the PBS region.  The radiolabelled template RNA by itself migrated as a single band, 
which served as a negative control (Figure 3.3 lane 1).   The NC alone was able to facilitate  tRNALys,3 
annealing to the PBS region as evidenced by the upward band shift (Figure 3.3 lanes 16, 17 and 18) as 
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shown previously in Figure 3.2 (lanes 8, 9 and 10).   However adding a 4-fold excess to the template 
RNA of either native (Figure 3.3 lanes 3, 4 and 5), F/W mutant (Figure 3.3 lanes 6, 7 and 8), E259Q 
(Figure 3.3 lanes 10, 11 and 12) or the clinical H186R mutant (Figure 3.3 lanes 13, 14 and 15) did not 
result in the inhibition of NC mediated strand annealing of the tRNALys,3.  From this it can be 
concluded that it is unlikely that Apo3G nor any of the mutants used in this study inhibit NC mediated 
of tRNALys,3.  This appears to be the case regardless of either Apo3G or NC concentration. 
 
 
 
Figure 3.3 APOBEC3G does not inhibit NC mediated strand annealing when the concentration of 
NC is low.  Template RNA (104 nt) 32P-labeled at the 5'-end was added to reactions at a concentration 
of 20 nM.   NC was added to the reactions at a ratio to the template RNA of 21:1.  Native Apo3G and 
mutants were added to the reactions at a ratio to the template RNA of 4:1.   NC was added to the 
reaction in the presence of Apo3G (lanes 3-5), F/W mutant (lanes 6-8), E259Q (lanes 10-12), H186R 
(lanes 13-15).  Lanes 1and 9, in which PBS RNA is present alone, serves as a negative control.  Lanes 
16-18, which are NC alone, serve as a positive control. Samples were taken at 5, 10 and 30 min. 
Groups of timed assays are denoted with a triangle.  
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3.1.4 APOBEC3G does not compete with nucleocapsid for template RNA binding 
 
We hypothesized that because both NC and Apo3G can both bind to RNA that they could 
possibly compete for RNA binding.  To determine if Apo3G could compete with NC for RNA binding, 
and possibly inhibit NC-mediated strand annealing, we used rotational anisotropy to determine the 
apparent dissociation constant (Kd) of Apo3G and NC for a F-labeled version of the template RNA.   
Here wanted to assess whether or not prebinding RNA with Apo3G could cause any change in the 
affinity of NC for RNA and vice versa, which would be indicative of Apo3G and NC competing for the 
RNA substrate. 
We prebound specific concentrations of Apo3G to the RNA and then used this as the substrate 
for NC binding experiments and vice versa. Taking into account results of the annealing assay, our 
hypothesis was that Apo3G and NC would not interfere with each other’s binding to the RNA 
substrate. The apparent Kd values of NC and Apo3G for the RNA were similar (Table 3.1, 402 and 383 
nM, respectively). Prebinding of the template RNA with either a 10: 1 (500 nM) or 17:1 (850 nM) ratio 
of Apo3G to the template RNA did not result in a significant difference in the apparent Kd of NC 
(Table 3.1, 368 and 441nM, respectively).  Similarly, prebinding the template RNA with either a 10: 1 
or 17:1 ratio of NC did not result in a significant difference in the apparent Kd of Apo3G (Table 3.1, 
501 and 489 nM, respectively).   It is therefore unlikely that Apo3G competes with NC for RNA 
binding.  This data is congruous with the annealing assay data which also suggests that Apo3G does not 
interfere with NC mediated strand annealing (Figures 3.1 and 3.3).  
 
Table 3.1 Apparent dissociation constants (Kd) of native APOBEC3G and nucleocapsid with for 
template RNA. The Kd values shown are for Apo3G and nucleocapsid individually, or with either 500 
nM or 850 nM Apo3G or nucleocapsid prebound to the template PBS RNA.  
 
Nucleocapsid 
prebound to  
RNA (nM) 
Apo3G       
Kd (nM) 
Apo3G      
prebound to  
RNA (nM) 
Nucleocapsid 
Kd (nM) 
0 383 ± 205  0 402 ± 209  
500 501 ± 1  500 368 ± 149  
850 489 ± 42  850 441 ± 47  
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3.2 APOBEC3G inhibition of reverse transcriptase-mediated polymerization on an RNA/RNA 
primer/template  
 
3.2.1 APOBEC3G inhibits reverse transcriptase-mediated primer extension  
 
 As Apo3G has a strong affinity for ssRNA ( (Chelico et al., 2010) and Table 3.1), we 
hypothesized that Apo3G could inhibit RT mediated primer extension by either physically blocking RT 
from adding nucleotides or by competing with RT for RNA binding. To establish the degree of 
inhibition of RT-mediated DNA synthesis by Apo3G we analyzed (-) DNA primer extension activity.  
For the assay we heat annealed a synthetic RNA primer in lieu of the tRNALys,3 to the template RNA 
and assayed the products by gel electrophoresis (Figure 3.4, sketch). This is a model system for (-) 
DNA primer extension synthesis (Figure 1.2). RT is able to extend ~70% of the primer and 5% of these 
products result in full length transcripts (Figure 3.4 A). When Apo3G was added to the primer 
extension reaction at a 4-fold ratio over the primer/template, which is the estimated concentration in a 
ΔVif HIV virion (see Section 2.0), we observed a decrease in the efficiency of primer extension (Figure 
3.4 B, 4:1). The total amount of primer initiation that is inhibited in the presence of Apo3G ranges from 
2.4-fold (2.5 min) to 1.5-fold (60 min) (compare Figure 3.4 B and Figure 3.4 A). Apo3G also changes 
the population of extension products and amount of fully extended primer. Apo3G prevents the 
majority of primer from being elongated past ~ 12 nt (compare Figure 3.4 B and Figure 3.4 A). Most 
notably, the presence of Apo3G (4:1, Figure 3.4 B) is able to decrease the amount of fully extended 
primer by 30-fold in comparison to primer extension by RT (Figure 3.8).  Addition of greater amounts 
of Apo3G (32:1, Figure 3.4 C) resulted in almost the same amount of total primer extension as Apo3G 
(4:1, Figure 3.4 B) with percent primer extension reaching 34% and 47% at 60 min, respectively. 
However, the final extension product for the assay on which 32:1 ratio of Apo3G: primer/template used 
by analyzing integrated gel band intensities was not detectable (Figure 3.4 C and Figure 3.8).  These 
results suggest that on an RNA/RNA primer/template, Apo3G primarily impacts primer elongation and 
the ability of RT to synthesize full length transcripts, but can also inhibit RT by preventing primer 
initiation perhaps by blocking RT from accessing the primer template junction. 
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Figure 3.4 Reverse transcriptase-mediated primer extension in the absence and presence of  
native APOBEC3G.  A 32P-labeled RNA primer was heat annealed to a 104 nt template RNA 
containing the PBS (sketch). Complete extension of the primer results in a DNA of 58 nt. (A) primer 
extension by RT. (B-C) primer extension by RT in the presence of either a 4:1 (B) or 32:1 (C) ratio of 
native Apo3G to the primer/template. The primer/template concentration was 20 nM. The 4:1 ratio of 
Apo3G to primer/template (B, 80 nM Apo3G) represents the concentration of Apo3G estimated to be 
found in a ΔVif HIV virion (see Section 2.0). Samples were collected at the following times: 2.5, 5, 10, 
15, 30 and 60 min. Total primer extension (%) averaged from two independent trials and the range (±) 
of the data is shown below gels.  
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3.2.2 Oligomerization facilitates APOBEC3G inhibition of reverse transcriptase mediated primer 
extension 
  
 We hypothesized that oligomerization may be important for Apo3G inhibition of RT mediated 
primer extension.  Being able to form higher order structures likely enables Apo3G to block RT primer 
extension activity.  Based on our hypothesis, if Apo3G were to lose this ability, we predicted that 
Apo3G inhibition of RT mediated primer extension activity would be at a deficit.  We chose to use the 
Apo3G F/W mutant to assess whether or not oligomerization is important for RT inhibition.  The 
Apo3G F/W mutant has been shown to exist as a monomer in solution and when bound to DNA or 
RNA (Chelico et al., 2010; Huthoff et al., 2009).   
 Under the same conditions used for native Apo3G, we tested if the F/W mutant could inhibit 
RT-mediated primer extension (Figure. 3.5). The F/W mutant was found to inhibit RT-mediated primer 
initiation to the same extent as native Apo3G (compare Figure 3.4 B and Figure 3.5 A, Primer 
extension (%)).  However, in the presence of the F/W mutant, RT is able to undergo primer elongation 
past ~12 nt (Figure 3.5 A), similar to extension in the absence of native Apo3G (Figure 3.4 A). The 
F/W mutant inhibits RT-mediated synthesis of full length products by only 1.3-fold, which is less than 
Native Apo3G (Figure 3.8). Upon increasing the concentration of the F/W mutant, the final extension 
products formed by RT are inhibited more than at the lower concentration (Figure 3.8 and compare 
Figure 3.5 B and Figure 3.5 A), demonstrating that the deficiency of the F/W mutant to inhibit RT 
primer extension can be partially recovered by increasing the enzyme concentration. However, all 
together the results indicate that the absence of oligomerization hinders the ability of Apo3G to inhibit 
RT-mediated primer extension. 
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Figure 3.5 Impaired inhibition of reverse transcriptase-mediated primer extension by the 
monomeric F/W mutant.  A 32P-labeled RNA primer was heat annealed to a 104 nt RNA template 
containing the PBS (sketch). Complete extension of the primer results in a DNA of 58 nt. (A-B) primer 
extension by RT in the presence of either a 4:1 (A) or 32:1 (B) ratio of F/W mutant to the 
primer/template. The primer template concentration was 20 nM. Samples were collected at the 
following times: 2.5, 5, 10, 15, 30 and 60 min. Total primer extension (%) averaged from two 
independent trials and the range (±) of the data is shown below gels.  
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3.2.3 Inhibition of reverse transcriptase-mediated primer extension by the catalytic mutant 
E259Q 
 
 We hypothesized that in addition to losing the ability to deaminate, that the Apo3G E259Q 
deamination mutant may also be defective in its ability to inhibit RT mediate primer extension.  This 
hypothesis is based on the presumption that this mutation, in addition to abrogating the ability of 
Apo3G to deaminate ssDNA, may also cause structural changes that could alter its ability to inhibit RT 
mediated primer extension.  This would therefore account for its deficiency to inhibit HIV infectivity 
found in other studies (Bishop et al., 2008; Mbisa et al., 2007; Miyagi et al., 2007; Schumacher et al., 
2008).      
 The E259Q mutant is able to decrease the efficiency of RT-mediated primer extension (Figure 
3.6 A). The primer initiation by RT is decreased 2.5-fold (2.5 min) to 1.6-fold (60 min) in the presence 
of E259Q, similar to native Apo3G (compare Figure 3.6 A and Figure 3.4 B). In contrast to native 
Apo3G, the E259Q mutant only causes a 4-fold decrease in the amount of final extension product (58 
nt, Figure 3.6 A and Figure 3.8) compared to a 30-fold decrease with native Apo3G (Figure 3.4 B and 
Figure 3.8). At a higher concentration of E259Q the inhibition of primer initiation is similar to native 
Apo3G (32:1, compare Figure 3.6 B and Figure 3.4 C), but fully extended products are detectable 
whereas they were not with native Apo3G (Figure 3.8). 
 The E259Q mutant is therefore able to reduce the efficiency of RT-mediated primer extension in 
a similar fashion to native Apo3G.  However that the ability of E259Q to prevent the formation of final 
extension products is diminished relative to native Apo3G suggesting that the E259Q mutant is 
fundamentally different than native Apo3G beyond its ability to deaminate. This indicates that this 
mutation may cause more than just a loss in the ability to deaminate making it poor proxy for Native 
Apo3G. 
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Figure 3.6 The catalytic mutant E259Q inhibits reverse transcriptase-mediated primer extension. 
A 32P-labeled RNA primer was heat annealed to a 104 nt template RNA containing the PBS (sketch). 
Complete extension of the primer results in a DNA of 58 nt. (A-B) primer extension by RT in the 
presence of either a 4:1 (A) or 32:1 (B) ratio of E259Q to the primer/template. The primer/template 
concentration was 20 nM. Samples were collected at the following times: 2.5, 5, 10, 15, 30 and 60 min. 
Total primer extension (%) averaged from two independent trials and the range (±) of the data is shown 
below gels.  
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3.2.4 Inhibition of reverse transcriptase-mediated primer extension by the clinical mutant H186R 
 
 The Apo3G H186R clinical mutant is associated with HIV patients whose infection quickly 
progresses to AIDS (An et al., 2004).  We hypothesized that the diminished ability to restrict HIV 
infection of patients that harbour the Apo3G H186R mutation may be attributed to a reduced capacity 
to inhibit RT primer extension.   
 The H186R clinical mutant can inhibit RT mediated primer extension.  Its ability to inhibit 
overall primer extension is similar to Apo3G (compare primer extension (%), Figure 3.4 B,C and 
Figure 3.7).  The H186R mutant is less able to inhibit the formation of final extension products 
mediated by RT as compared to Apo3G when present at a ratio of 4:1 enzyme: primer/template (Figure 
3.8). However, the native and H186R Apo3G forms exhibit similar inhibition of the final extension 
product formation at a ratio of enzyme to the primer/template of 32:1 (Figure 3.8). 
 The Apo3G H186R mutant is able to restrict total and final extension products in a similar 
manner to Native Apo3G.  It is therefore unlikely that patients with the Apo3G H186R mutation have a 
reduced ability to inhibit RT mediated primer extension.  
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Figure 3.7 The clinical mutant H186R inhibits reverse transcriptase-mediated primer extension. A 
32P-labeled RNA primer was heat annealed to a 104 nt template RNA containing the PBS (sketch). 
Complete extension of the primer results in a DNA of 58 nt. (A-B) primer extension by RT in the 
presence of either a 4:1 (A) or 32:1 (B) ratio of H186R to the primer/template. The primer/template 
concentration was 20 nM. Samples were collected at the following times: 2.5, 5, 10, 15, 30 and 60 min. 
Total primer extension (%) averaged from two independent trials and the range (±) of the data is shown 
below gels.  
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3.2.5 Synthesis of full length reverse transcripts by reverse transcriptase in the absence and 
presence of native and mutant APOBEC3G 
 
 In addition to quantifying the overall primer extension, we examined the type of inhibition of 
primer extension products RT produced in the presence of the Apo3G forms.  When looking at the 
distribution of the final extension product bands, Apo3G at a concentration of 80 nM and with the 
primer template concentration of 20 nM (4:1 ratio), the ratio found in HIV virions when Vif is not 
present (Xu et al., 2007), can significantly reduce the quantity of the final extension product.  The 
quantity of final extension bands seen with no Apo3G present is 5% of the total extension products 
(Figure 3.8 A, Native, 4:1 and Figure 3.4 B lane 6), as compared to when there is no Apo3G present 
which results in the final extension products being made to 0.2% of the total extension products (Figure 
3.8, RT and Figure 3.4 A, RT).  At the 4:1 ratio, there is a decrease in the final extension product from 
RT alone for reactions in the presence of native Apo3G, F/W mutant, E259Q and H186R.  When the 
F/W mutant, E259Q, or H186R are used, we see that their ability to reduce the quantity of final 
extension products in the final band is less than native Apo3G (Figure 3.8, 4:1; Figure 3.5 A lane 6, 
Figure 3.6 A lane 6 and Figure 3.7 A lane 6, respectively).   
This trend is also followed when the Apo3G native and mutant proteins are added at higher ratio 
(32:1) to the primer/ template (Figure 3.8 and 3.4 C). At the 32:1 ratio, the final extension product band 
of Apo3G is not detectable on the gel. The quantity of final extension product band from reactions with 
the F/W mutant (Figure 3.8A, 1.4%),  E259Q (Figure 3.8 A, 0.5%), and H186R (Figure 3.8A, 0.1%) 
are less than at the lower concentration, but the F/W and E259Q mutants still inhibit the accumulation 
of reverse transcripts less than native Apo3G.   
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Figure 3.8 Synthesis of full length reverse transcripts by reverse transcriptase in the absence and 
presence of native and mutant APOBEC3G.  A, Comparison of normalized percent final extension 
product (58 nt) of RT in the absence or presence of a 4:1 or 32:1 ratio of native Apo3G, F/W mutant, 
E259Q or H186R to the primer/template. The primer/template concentration was 20 nM. The 4:1 ratio 
of Apo3G to primer/template (80 nM) represents the concentration of Apo3G estimated to be found in a 
ΔVif HIV virion. The final extension product value has been normalized to the total primer extension of 
RT. The percent final extension product for native Apo3G 32:1 ratio could not be calculated since there 
was no detectable band from gel assays. Data is summarized from analysis of the 60 min sample from 
experiments shown in Figure 3.4-3.7. The data shown is from two independent trials and the range of 
the data is based on the standard deviation between the two trials (error bars). 
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3.2.6 Binding affinity of APOBEC3G forms for the primer/template correlates with the ability to 
inhibit reverse transcriptase 
 
 We hypothesized that the difference in the ability of native Apo3G and the mutants (F/W and 
E259Q) to inhibit RT-mediated primer extension may be attributed to their binding affinity for 
primer/template RNA.  Additionally, we hypothesized that if Apo3G had a stronger affinity for the 
primer/template that it could possibly compete with RT for binding to the primer/template. 
   We therefore used fluorescence depolarization (rotational anisotropy) to determine the 
apparent Kd of native and mutant Apo3G and RT for the primer/template. Native Apo3G binds the 
primer template with ~3-fold greater affinity than RT (Table 3.2, Kd of 192 and 549 nM, respectively). 
The Apo3G mutants both bind the primer template with less affinity than native Apo3G and have Kd 
values that are more similar to RT (Table 3.2, F/W mutant, 354 nM; E259Q, 477 nM). The binding data 
demonstrates that E259Q cannot be used interchangeably with native Apo3G when a deamination-null 
mutant is required because the binding affinities for the template differ by 2.5- fold.  
 The data suggest that binding affinity for RNA may contribute to the ability of Apo3G to inhibit 
synthesis of reverse transcripts since the F/W mutant and E259Q which inhibit RT-mediated DNA 
synthesis less than native Apo3G (Figure 3.8), even at the 32:1 ratio, also bind the primer/template with 
less affinity.  Also it is suggested that Apo3G could compete with RT for primer/template binding as a 
substrate as the apparent Kd of native Apo3G for the primer/template is less than the apparent Kd of RT 
for the primer/template 
 
Table 3.2 Apparent dissociation constants (Kd) of reverse transcriptase and native and mutant  
APOBEC3G. 
 
 
Enzyme Kd (nM) 
native Apo3G 192  ± 39 
F/W mutant 354 ± 26 
E259Q 477 ± 69 
RT 549 ± 42 
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3.2.7 Combined binding of reverse transcriptase and APOBEC3G to primer/template RNA 
 
 As an indication of whether the higher binding affinity for the primer/template of native 
Apo3G decreased the ability of RT to bind the primer/template, we used electrophoretic mobility shift 
assays where RT competed for primer/template from prebound Apo3G. The RT alone can saturate the 
primer/template when a 25-fold excess of RT to primer/template is added (Figure 3.9 B, lane 7, 1240 
nM). We tested whether prebinding a 10-fold excess of Apo3G to the primer/template would increase 
the amount of RT needed to saturate the primer/template.  If RT binding to the primer/template is not 
affected by the presence of native Apo3G we would expect that the RT would still be able to saturate 
the substrate. Because the Apo3G added as a competitor is able to shift 35% of the substrate (Figure 3.9 
C, lane 2) we expect that all the substrate should be shifted with less RT. Figure 3.9C shows that RT is 
not prevented from binding to the primer/template and can saturate the primer/template at ~620 nM, 
rather than at 1240 nM (Figure 3.9 C, lanes 8 and 9). The E259Q and the F/W mutant were also found 
to not affect the ability of RT to bind the primer/template (Figure 3.9 D and Figure 3.9 E, respectively).  
The ability of both Apo3G and RT to bind the primer/template may be because the RT preferentially 
binds at the primer/template junction, whereas Apo3G can bind anywhere along the RNA molecule. 
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Figure 3.9 Visualization of combined binding of native APOBEC3G and reverse transcriptase to 
the primer/template using an electrophoretic mobility shift assay.   (A-B) Apo3G (A) or RT (B) 
was titrated into sample reactions containing 50 nM fluorescein (F)-labelled primer/template at 
concentrations of 60, 120, 240, 480, 620, 1240 and 2480 nM.  (C-E) RT was titrated into sample 
reactions containing 50 nM fluorescein (F)-labelled primer/template at concentrations of 60, 120, 240, 
480, 620, 1240 and 2480 nM with 480 nM native Apo3G (C), 480 nM E259Q (D) or 480 nM F/W 
mutant (E) prebound to the primer/ template. Free and bound RNA are denoted on gels. (C) shift of 
prebound Apo3G (lane 2, 480 nM) is shown on gel in comparison RT bound alone at 480 nM (lane 3) 
to assist in differentiating the combined Apo3G/RT shift from an RT shift. D, shift of prebound E259Q 
(lane 2, 480 nM) is shown on gel in comparison RT bound alone at 480 nM (lane 3) to assist in 
differentiating the combined E259Q/RT shift from an RT shift. E, shift of prebound F/W (lane 9, 480 
nM) is shown on gel in comparison RT bound alone at 480 nM (lane 10) to assist in differentiating the 
combined F/W / RT shift from an RT shift. 
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3.2.8 Protein-protein interactions between APOBEC3G and reverse transcriptase 
 
 We hypothesized that Apo3G could inhibit RT by physically binding to it and preventing it from 
reverse transcribing –ssRNA into +ssDNA.  We chose to use rotational anisotropy to test protein-
protein interactions between RT and Apo3G.  By using a fluorescein labelled Apo3G (F-Apo3G), we 
found that Apo3G can interact with F-Apo3G with low affinity (Kd 3.5 µM, Figure 3.10).  RT also 
binds to F-Apo3G with a low affinity (Kd 4 µM, Figure 3.10). As a negative control, we assessed 
whether the monomeric F/W mutant could interact with native Apo3G.  As expected, we found no 
detectable interaction between F-Apo3G and the F/W mutant (Figure 3.10).  This data demonstrates 
that protein-protein interactions between RT and Apo3G are possible, but not as likely to happen in 
vivo as binding to RNA since the protein concentrations required for RT and Apo3G to interact are in 
the micromolar range, whereas the affinities for RNA are in the nanomolar range (Table 3.2).  
 
 
 
 
Figure 3.10 Analysis of interaction between APOBEC3G forms and reverse transcriptase to 
fluorescently labelled APOBEC3G by steady-state fluorescence depolarization. Apparent 
dissociation constants (Kd) were determined by titrating increasing concentrations (x-axis) of RT, native 
Apo3G or F/W mutant to 50 nM of fluorescein (F)-labelled native Apo3G. RT binds F-Apo3G with an 
apparent Kd of 4 μM, which is similar to the apparent Kd of native Apo3G and F-Apo3G (3.5 μM).  
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3.2.9 Using pyrrolo-C to detect protein induced conformational changes in primer/template RNA 
 
Previously, native Apo3G has been shown to cause a change in the structure of ssDNA, based 
on monitoring changes in pyrollo-dC fluorescence (Chelico et al., 2008). Pyrollo-dC is a fluorescent 
nucleotide analogue that can be used to monitor changes in the local structure of the ssDNA. An 
increase in fluorescence of the pyrollo-dC is interpreted to mean that a change in the structure of the 
ssDNA such as bending or wrapping has occurred. We tested a parallel situation with pyrollo-C 
embedded in RNA. We found that both native and E259Q Apo3G were unable to cause a change in 
pyrollo-C fluorescence (Figure 3.11). The F/W mutant was able to cause a 2.5-fold change in the 
pyrollo-C fluorescence (Figure 3.11). Since the F/W mutant displayed the least inhibition of RT-
mediated DNA synthesis, the results suggest that changing the structure of the RNA is not a factor in 
the mechanism by which Apo3G limits synthesis of DNA by RT. 
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Figure 3.11 Conformational modulation of RNA by reverse transcriptase and APOBEC3G. 
Fluorescence emissions of 100 nM pyrrolo-C labelled RNA (sketch) were monitored after the addition 
of 1.2 μM enzyme. Emissions are plotted as fluorescence value relative to RNA alone (value of 1.0) for 
native Apo3G, E259Q and F/W mutant. The data show that the F/W mutant is able to cause a 2.5-fold 
increase in the relative fluorescence of pyrrolo-C, indicating that the structure of the RNA is altered by 
F/W mutant binding.  Native Apo3G and E259Q are not able to cause a significant change in pyrrolo-C 
fluorescence. Data is from two independent trials and the range of the data is shown.  
 
3.3 RNAseH activity 
 
RT utilizes an RNAseH domain to degrade template RNA during HIV reverse transcription.  We 
hypothesized that if Apo3G could bind RT through a protein-protein interaction it could inhibit 
RNAseH activity of RT. Since Apo3G does not bind RNA/DNA hybrids with high affinity (Iwatani et 
al., 2006), it is unlikely that Apo3G can inhibit RNAseH activity through binding nucleic acids and 
physically blocking RT. With the results from the protein-protein anisotropy (Figure 3.10), we 
hypothesized that Apo3G could not inhibit RNAseH activity. We tested the RNAseH activity of RT 
using two methods. 
5' 3'P
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3.3.1 The analysis of RNAseH activity during primer/template extension in the absence and 
presence of APOBEC3G  
 
 The first RNAseH assay employs a 
32
P-labelled PBS template RNA that is annealed to an 
unextended RNA primer to form the primer/template such as that used for experiments described in 
Section 3.2.  In this assay, degradation can only take place once the RNA/DNA hybrid is formed by RT-
mediated DNA synthesis. Therefore, we do not expect to see 100% RNA degradation based on results 
from primer extension assays (Figure 3.8). When RT is present alone, RNA degradation is detected 
(Figure 3.12 A).  However when Apo3G is present at a 4:1 ratio to the primer/template, a reduction in 
the quantity of RNA degradation is observed (Figure 3.12 B).  The addition of the Apo3G monomeric 
mutant F126A/W127A does not appear to result in a reduction in RNA degradation (Figure 3.12 C).  
More similar to native Apo3G, when the deamination mutant E259Q and the clinical mutant H186R are 
used, there is minimal RNA degradation (Figure 3.12 D and E, respectively). The presence of Apo3G 
forms that inhibit synthesis of final extension products the greatest (Figure 3.8) correlated with 
inhibition of RNAseH activity. Since the RNAseH activity requires a DNA/RNA hybrid, Apo3G 
appears to be inhibiting RNAseH activity indirectly (Figure 3.12).  
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Figure 3.12 Measurement of RNAseH activity during primer extension.  Reactions contained 
32
P-
labelled template RNA annealed to an unextended RNA primer to form the primer/template.  The 
primer/template was added at 20 nM in the presence of RT buffer, NC (350 nM) and RT (960 nM). 
RNAseH activity was measured by degradation of the RNA in the absence (A), or presence of a 4-fold 
excess to the primer/template (80 nM) of native Apo3G (B), F/W mutant (C), E259Q (D) or H186R 
(E). Samples were taken at 2.5, 5, 10, 15, 30 and 60 min.  The single lane by itself (left) shows the 
unreacted primer/template (p/t) as a negative control.  
 
3.3.2 The analysis of RNAseH activity using a RNA/DNA hybrid in the absence and presence of 
APOBEC3G 
 
 In a second RNAseH assay, we annealed a full complement DNA strand to the 32P-labelled 
RNA template. In this type of assay, we start with the RNAseH substrate fully available and expect to 
obtain 100% cleavage of the template RNA. The DNA/RNA hybrid substrate shows significant 
degradation by RT, as expected (Figure 3.13 A). None of the Apo3G forms at either the low (4:1) or 
NC/RT Apo3G F/W mutant E259Q H186R
A B C D E
Time (min)Time (min)Time (min) Time (min) Time (min)
p/t
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high (32:1) ratios to the primer/template inhibited RNAseH-mediated RNA degradation. 
 
 
 
Figure 3.13 The presence of APOBEC3G does not inhibit reverse transcriptase mediated RNAseH 
degradation of template RNA. 32-P labelled template RNA was heat annealed to a full complement of 
DNA to create a substrate for RNAseH.  The substrate was added to reactions at 20 nM in the presence 
of RT buffer.  Reactions contained 350 nM NC and 960 nM RT in the absence (A) or presence of 
Apo3G forms added at various ratios to the primer template: of native Apo3G, 4:1 (B), native Apo3G, 
32:1 (C), F/W mutant, 4:1  (D), E259Q, 4:1  (E) or H186R, 4:1  (F). Samples were taken at 2.5, 5, 10, 
15, 30 and 60 min. The single lane by itself (left), shows the unreacted primer template (p/t) as a 
negative control.  
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4.1 Nucleocapsid-mediated annealing of tRNALys,3 in the presence of APOBEC3G 
 
 Annealing of the tRNALys,3 to the PBS region is the first important step of reverse transcription.  
RT needs the tRNALys,3 to be annealed to the PBS region as the tRNALys,3 functions as a primer that RT 
recognizes as a start site to begin reverse transcribing.   This first step of reverse transcription is a 
logical place to begin investigating whether or not it is here that the deamination independent 
mechanism of Apo3G occurs, because if it did, it would impact reverse transcription events 
downstream of it.  However, as evidenced by our annealing assays, the presence of Apo3G appears to 
not be able to inhibit NC-mediated strand annealing at low (4:1) or high (32:1) ratios of Apo3G to the 
primer/template (Figure 3.1).  After titrating the concentration of NC down from an excess to 
determine the lowest level that allows NC mediated strand annealing to occur (Figure 3.2), we still see 
that neither Apo3G, nor any of the Apo3G mutants are able to inhibit NC mediated strand annealing 
(Figure 3.3).  Furthermore, strand annealing reactions were set up with Apo3G prebound to the 
substrate to give Apo3G an “advantage” however, according to rotational anisotropy data (Table 3.1), 
this step is inconsequential as pre-binding the RNA with Apo3G appeared to not have an effect on the 
apparent Kd of NC.  Similar to native Apo3G, both the monomeric F/W mutant and the catalytic mutant 
E259Q were unable to cause any discernible decrease in strand annealing (Figure 3.3).  Accordingly, 
prebinding of Apo3G to RNA was unable to cause significant change in the affinity of NC for the RNA 
(Table 3.1).  This suggests that although Apo3G and NC have similar binding affinities for the template 
RNA (Table 2, Kd of 402 and 383 nM, respectively), neither can compete the other off of the RNA 
substrate. 
 This agrees with Iwatani et al., who also show that the addition of Apo3G has no impact on NC 
mediated tRNALys,3 annealing (Iwatani et al., 2007).  Contrary to these findings Guo et al. provide 
evidence that Apo3G can inhibit NC mediated strand annealing (Guo et al., 2007).  Guo and colleagues 
show that this occurs only at particular concentrations of Apo3G and NC that may not accurately 
reflect the ratios of these proteins to the tRNALys,3 and RNA that is found in vivo (Guo et al., 2007).  
The assay we used however only detects changes in annealing as a function of a change in band 
migration.  The annealing assay however does not detect whether or not the tRNALys,3 is completely or 
partially annealed, which at the 3' of  the tRNALys,3 would obviously have an impact on primer 
extension initiation if it was not completely annealed. 
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4.2 Inhibition of reverse transcriptase-mediated primer extension by APOBEC3G is dependent 
on the ability of APOBEC3G to oligomerize and bind RNA with a high affinity 
 
 After the tRNALys,3 has been annealed to PBS region, the next step of HIV reverse transcription 
is for RT to initiate primer extension.  As Apo3G can bind to ssRNA, it was logical to hypothesize that 
it could bind to the PBS region of RNA and physically block RT from reverse transcribing, and 
therefore inhibit primer extension.  Any changes in RT mediated primer extension with Apo3G present 
therefore could be attributed any of several of the predicted mechanisms of the deamination 
independent mode of Apo3G.  The mechanisms that we chose to test were Apo3G oligomerization, the 
affinity of Apo3G for primer/template RNA, protein-protein interactions between RT and Apo3G and 
conformational changes of RNA caused by Apo3G.      
 We have shown that Apo3G can inhibit primer extension (Figure 3.4).  We also investigated 
several mutant forms of Apo3G to elucidate a mechanism by which Apo3G could inhibit RT-mediated 
primer extension.  The monomeric F/W mutant (Figure 3.5), the catalytic mutant E259Q (Figure 3.6), 
and the clinical mutant H186R (Figure 3.7) inhibited overall primer extension to the same extent as 
native Apo3G (Figure 3.4), but showed varying degrees of deficiency in attenuating production of the 
final extension product (Figure 3.8). 
 The data suggest that oligomeric versions of Apo3G that have a binding affinity for the RNA 
template which exceeds RT for an RNA template can partially block RT-mediated DNA synthesis 
(Table 3.2 and Figure 3.8). Data showing the deficiency of the monomeric F/W mutant in reverse 
transcriptase inhibition indicates that the ability to oligomerize on the RNA template appears to be the 
most important factor that enables inhibition of RT-mediated DNA synthesis (Figure 3.8). That 
oligomers of E259Q can bind RNA with a similar affinity to the F/W mutant (Table 3.2), but inhibit the 
formation of reverse transcripts with a median effectiveness in comparison to the F/W mutant and 
native Apo3G (Figure 3.8), suggests that RNA binding affinity is involved in the mechanism, although 
second in significance to oligomerization.  
 This suggests that the higher-order structures of Apo3G on RNA may act as a physical block. 
This is in contrast to a previous mechanism suggested for the deamination-independent mode of 
inhibition byApo3G that hypothesized that RNA binding ability alone was sufficient (Iwatani et al., 
2007). Here we find that the mechanism is not only based on RNA binding, but also in what form the 
enzyme binds the template.  Monomers of the F/W mutant and oligomers of E259Q, which have the 
similar binding affinity for the template (Table 3.2), have differential abilities to inhibit DNA synthesis 
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by RT (Figure 3.5, Figure 3.6 and Figure 3.8). Since Apo3G does not block RT from binding the 
primer/template (Figure 3.9), then RT would presumably have to displace Apo3G from the template to 
continue primer elongation. Accordingly, the data predict that Apo3G monomers can be displaced 
more easily by RT than Apo3G oligomers.  In support of this prediction, the F/W mutant has been 
found to exhibit a 3-fold faster off-rate from ssDNA than native Apo3G (Chelico et al., 2010). 
 Another prediction of a model in which RT must displace Apo3G to extend the primer is that 
protein-protein interactions between RT and Apo3G do not play a role. Using a fluorescein labeled 
Apo3G (F-Apo3G), we found that Apo3G can interact with F-Apo3G with low affinity (Kd 3.5 µM, 
Figure 3.10).  RT also binds to F-Apo3G with a low affinity (Kd 4 µM, Figure 3.10). All together these 
data demonstrate that protein-protein interactions between RT and Apo3G in solution are unfavourable.  
It is therefore likely that Apo3G does not inhibit primer extension by binding to RT in vivo.  
 It is also not likely that Apo3G mediates conformational changes in RNA that enable it to better 
inhibit primer extension.  We see that only the F/W mutant is able to cause a significant change in RNA 
conformation (Figure 3.11).  As F126A/W127A inhibited primer extension the least (Figure 3.8), the 
data suggest that conformational changes in RNA likely have little bearing on native Apo3G’s ability 
to inhibit primer extension.   
 However using the same reasoning that oligomerization is important for inhibiting the 
production of final extension products, perhaps taking away the ability for Apo3G to oligomerize, as in 
the case of the F126A/W127A oligomerization mutant, allows Apo3G to cause a conformational 
change in the substrate RNA.  This could result in a RNA conformation that is more conducive to 
reverse transcription, therefore giving RT a better substrate to reverse transcribe which may explain in 
part why the F126A/W127A mutant does not  inhibit the formation of final extension as well as native 
Apo3G. 
 A study by Iwantani et al. also assessed the ability of Apo3G to inhibit primer extension 
(Iwatani et al., 2007).  They found that Apo3G can inhibit RT mediated primer extension.  However, 
the concentration of Apo3G relative to the primer/template used in most experiments was 16-fold 
higher than the primer template concentration, which is far greater than ratios used in this research and 
those estimated to be found in vivo (Table 1.1). Further, the RT concentration was at an equimolar ratio 
to the primer/template which is very low compared to in vivo estimations (Table 1.1). This ultimately 
raised questions as to whether or not Apo3G could actually inhibit primer extension under conditions 
that more accurately reflect in vivo conditions.  In our studies we not only show that Apo3G can inhibit 
primer extension, but also that Apo3G can inhibit RT mediated primer extension when it is present at a 
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concentration that more accurately reflects the in vivo concentrations of all of the reverse transcription 
components.  In addition to this, we suggest a mechanism for this inhibition which is based on the 
ability of Apo3G to oligomerize and on the affinity Apo3G for the primer/template RNA. 
 
4.3 The use of E259Q as a null deaminase mutant 
 
 Previous studies have shown that E259Q was unable to inhibit the formation of reverse 
transcripts thereby suggesting that deamination was required (Mbisa et al., 2007; Miyagi et al., 2007; 
Schumacher et al., 2008).  Here we show that E259Q is not biochemically the same as native Apo3G. 
The E259Q mutation causes a 2.5-fold decrease in primer/template binding affinity (Table 3.2, native 
Apo3G Kd 192 nM; E259Q Kd 477 nM).  Although nucleic acid binding of Apo3G is largely contained 
within CD1 (Chelico et al., 2010; Chen et al., 2008) , the mutation of Glu259 in the active site CD2 is 
expected to affect substrate binding (Table 3.2). That E259Q is not biochemically similar to native 
Apo3G prevents interpretation of the importance of deamination in HIV inhibition using this mutant 
alone.  Even with the decreased ability of E259Q to bind RNA, we found that it could still inhibit 
formation of reverse transcripts although 7-fold less than native Apo3G (Figure 3.8).  This is in 
agreement with Bishop et al. (Bishop et al., 2008) that found the E259Q mutant to inhibit reverse 
transcripts but to a lesser extent than native Apo3G.   
 
4.4 RNAseH activity in the presence of APOBEC3G 
 
 Before RT can begin copying the (-) strand DNA into (+) strand DNA, it must first degrade the 
RNA that it used as a template for the (–) strand DNA synthesis.  RT utilizes an RNAseH domain to 
degrade the (–) strand RNA that it recognizes in a DNA/RNA hybrid.  Our hypothesis was that Apo3G 
would not be able to inhibit the RNAseH activity of RT because of a low affinity for binding 
DNA/RNA hybrids (Iwatani et al., 2006), unless we found that there were a strong protein-protein 
interaction between RT and Apo3G.  As we did not find a strong protein-protein interaction between 
RT and Apo3G, we therefore did not expect Apo3G to inhibit RNAseH activity of RT (Figure 3.10).  
We chose to use RNAseH assays to assess whether or not this was the case.  When we used a full 
DNA/RNA hybrid as the substrate for the RT RNAseH in our RNAseH assay, we found that neither 
native Apo3G nor any the Apo3G mutants interfered with RNAseH-mediated RNA degradation 
(Figure 3.13).  However, when we assessed RNAseH activity in a primer/extension reaction (Figure 
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3.12), we found that RNAseH inhibition corresponded with inhibition of final extension product 
(Figure 3.12 and Figure 3.8).  This is due to the fact that the RNA primer must first be extended to form 
the RNAseH substrate. For example, we observed more RNA degradation when the F/W mutant was 
used than with native Apo3G (Figure 3.12). As a result, it can be said that Apo3G can indirectly inhibit 
RNAseH degradation by limiting the rate of primer extension.   
 Our results pertaining to the ability of  Apo3G to inhibit RNAseH activity of RT are similar to 
those of Iwatani et al. (Iwatani et al., 2007).  Even though the ratio of Apo3G:RNA is much higher in 
assays from the Iwatani et al. paper compared to our assays, their conclusion was that Apo3G did not 
inhibit the RT mediated RNAseH degradation of their RNA/DNA hybrid (Iwatani et al., 2007).
 Contrary to our results, the study of Li et al. concluded that Apo3G can inhibit the RNAseH 
activity of RT (Li et al., 2007).  Here Li et al. used only an RNA primer heat annealed to the DNA 
construct which resulted in less degradation products when Apo3G was present than when it was 
absent (Li et al., 2007).   They claim that Apo3G can therefore directly inhibit RNAseH activity. This is 
similar to our results (Figure 3.12) with a primer/template in which we observed a decrease in 
degradation products from RT alone when Apo3G is present (Figure 3.4), but we attribute this to an 
indirect effect of Apo3G.  The decrease in degradation products of RT are likely due to Apo3G’s 
ability to inhibit primer extension (Figure 3.4A-B), and not direct RNAseH inhibition as when we use a 
full complement RNA/DNA hybrid, no degradation products are detected (Figure 3.13).  This further 
confirms that Apo3G does not inhibit RNAseH activity, but merely inhibits the formation of the 
substrate RNA/DNA hybrid.  
 
4.5 Overall Conclusion  
 
 Our data suggest a mechanism for how Apo3G can inhibit RT function. We show that this 
mechanism in not based upon the inhibition of NC mediated annealing of tRNALys,3 to RNA or a direct 
inhibition of RNAseH activity of RT by Apo3G.  We find that an important property of Apo3G 
contributing to the inhibition mechanism is its ability to oligomerize on nucleic acids (Chelico et al., 
2010; Chelico et al., 2008) (Figure 3.5 and Figure 3.8) and bind RNA with high affinity (Table 3.1). 
The F/W mutant that has been found to be a monomer in solution and when bound to nucleic acids 
(Chelico et al., 2010; Huthoff et al., 2009), inhibits the synthesis of the final extension product of RT 
20-fold less than native Apo3G at an enzyme:template ratio of 4:1 (Figure 3.8).  Furthermore, our 
biochemical characterization of E259Q indicates that it should not be used interchangeably with native 
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Apo3G in experimental systems that require a deamination null mutant. The E259Q mutant inhibited 
final extension products of RT 7-fold less than native Apo3G (Figure 3.8). This is presumably because 
the binding affinity of E259Q for the primer/template is similar to that of RT but lower than that of 
native Apo3G (Table 3.2, Kd 477 nM, 529 nM and 192 nM, respectively) and RT can more effectively 
displace E259Q than native Apo3G.  Our data suggests that oligomers of Apo3G may use the 
deamination-independent mode in vivo to inhibit or delay the formation of reverse transcripts, which 
can negatively impact HIV replication. Ascribing a mechanism to this mode of inhibition by Apo3G 
demonstrates that it could act in concert with deamination to inhibit HIV in vivo.   
 As more evidence is gained that validates the existence of an Apo3G deamination independent 
mechanism of HIV inhibition, it will likely be discovered that increasing intracellular levels of Apo3G 
would prove beneficial.  As we increased the levels of Apo3G from 80 nM to 640 nM we saw a 
decrease in the formation of total and final extension products (Figures 3.4 to 3.8).  Strategies that aim 
to increase intracellular levels of Apo3G will likely take advantage of this principle.  It is likely that we 
would see the level of HIV restriction, probably being inhibition of RT mediated primer extension as 
seen in this study in vitro, being directly proportionate to the amount of Apo3G being present 
intracellularly.  Being that the level of inhibition of the deamination dependent mechanism is likely 
limited by the CC motifs, having an alternate mode of HIV inhibition makes sense.  The potential for 
inhibition is therefore likely higher for the deamination independent mechanism than it is for the 
deamination dependent mechanism as, increasing the level of Apo3G would increase the deamination 
independent inhibition, supposedly reducing the efficiency of reverse transcription.  Whereas 
increasing the intracellular levels of Apo3G would, as previously mentioned, likely reach a limit where 
raising the intracellular level of Apo3G is no longer effective by just its deamination dependent 
mechanism alone.  Some studies claim that the experimental procedures used in cell culture, such as 
Apo3G plasmid over expression, is responsible for the observed Apo3G deamination dependent 
mechanism necessary (Bishop et al., 2008; Mbisa et al., 2007; Miyagi et al., 2007; Schumacher et al., 
2008).  Even if this is the case, the fact remains that increasing intracellular levels of Apo3G resulted in 
HIV inhibition, assuming that Apo3G was being expressed at levels higher than what is normally seen 
intracellularly, therefore validating the theory that HIV inhibition is directly proportionate to 
intracellular levels of Apo3G.   
 In this study we only tested the initial steps of reverse transcription, namely tRNALys,3 annealing 
and primer extension and RNAseH activity.  However the results of this study are likely applicable to 
subsequent steps of reverse transcription such as primer extension after the first and second strand 
58 
transfers and DNA elongation after both of these steps (Figure 1.2).  As long as there is Apo3G 
available, it should be able to inhibit primer extension by binding to RNA or ssDNA and preventing RT 
from efficiently polymerizing.  It is likely that Apo3G can inhibit primer extension during DNA 
elongation (Figure 1.2 Step 6) as Apo3G can bind to ssDNA, although with less affinity for than for 
ssRNA (Iwatani et al., 2006).  Whether or not Apo3G can reduce RT mediated primer extension on a 
DNA/DNA primer/template as well as on an RNA/RNA primer/template however remains to be seen. 
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5.1 In vivo expression of native, F126A/W127A and E259Q APOBEC3G  
 
 It would be interesting to see how well the results of this in vitro study translate in vivo.  We 
saw that Apo3G can inhibit primer extension and that this may be a result of the ability of Apo3G to 
oligomerize on RNA and also based on its affinity for the RNA primer/template.  We also saw that the 
E259Q deamination mutant may not serve as an ideal null proxy, as it does not behave exactly like 
Apo3G as based on our assays, the ability of E259Q to inhibit the formation of final extension products 
(Figure 3.6), and the affinity of E259Q for the RNA primer template is less than that of Apo3G (Table 
3.2).  We also saw that the monomeric F/W mutant was also less able to prevent the formation of final 
extension products as well as native Apo3G in addition to having a lower affinity for the RNA 
primer/template (Figure 3.5 and Table 3.2). To assess whether or not the lack of oligomerization 
(monomeric F/W mutant) or decreased binding affinity for the primer/template (monomeric F/W 
mutant and E259Q deamination null mutant) are important for having a reduced capacity to inhibit the 
formation of final extension products I would design an experiment to express these proteins by a gene 
knock in.  With choosing a cell line which expresses Apo3G, i.e., CEM cells, you could knock out the 
natively expressed Apo3G and knock in either E259Q Apo3G mutant or the F/W mutant.  Everything 
else being the same, the only difference would be the mutant variant of Apo3G being expressed, and 
not the level that it is being expressed at, thereby avoiding the over expression problem that hampered 
many past studies cells (Miyagi et al., 2007; Schumacher et al., 2008). This method is more likely to 
give a realistic representation of native Apo3G cellular cycling, and probably allow expression to be 
more akin to the levels seen with native Apo3G being expressed.  If any inhibition was seen with the 
E259Q deamination null mutant, it could likely be attributed to the Apo3G deamination independent 
mechanism, although it would likely be somewhat attenuated, as evidenced by data from our studies.  
As for the monomeric F/W mutant, any reduction in the ability to reduce HIV infectivity, likely by a 
reduced capacity to prevent the formation of, for example, completely reverse transcribed reverse 
transcripts in quantities similar to when native Apo3G is used, could be attributed to the lack of the 
ability to oligomerize.   
 
5.2 Implementing the tRNALys,3 in primer extension assays 
 
 Instead of using a heat annealed primer for our primer extension assays, it would interesting to 
design an assay using the tRNALys,3 annealed by NC.  Although our data suggests that as Apo3G does 
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not inhibit NC mediated annealing of tRNALys,3 to the PBS region, it would interesting to see if using 
the tRNALys,3 would have result in any differences in primer extension.  For example, perhaps the 
tRNALys,3 is better able to recruit RT than the annealed RNA primer, resulting in a faster rate of primer 
initiation. 
  
5.3 Assaying primer extension after the first and second strand transfers 
 
 Our assay only assessed whether or not Apo3G can inhibit primer extension of the PBS region.  
However there are multiple stages where the deamination independent mechanism of Apo3G can 
potentially impinge that we did not test.  For example, after the first strand transfer and second strand 
transfer, RT must resume primer extension and DNA elongation.  Using primer extension assays that 
model these events by using RNA or DNA templates that mimic these substrates would further verify 
the deamination independent mechanism of Apo3G.  It is quite likely that if Apo3G inhibits RT at 
every stage of proviral DNA synthesis, that reducing the efficiency of primer extension at each of these 
steps would have an additive effect which would translate to a synergistic effect in vivo.  Modest 
inhibition at multiple stages of reverse transcription would therefore likely have a big impact on the 
rate of formation of fully reverse transcribed proviral DNA ready to be integrated into the host genome.  
A significant reduction in the formation of provirus would therefore likely be seen, significantly 
restricting the HIV lifecycle. 
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